Infigratinib-d3

Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the FGFR family, with IC50 values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively[1].

Product Specifications

Product Name Alternative

BGJ-398-d3; NVP-BGJ398-d3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FGFR

Type

Isotope-Labeled Compounds

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

98.90

Solubility

DMSO : 12 mg/mL (ultrasonic; warming)

Smiles

CCN1CCN(C2=CC=C(NC3=NC=NC(N(C([2H])([2H])[2H])C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)=C3)C=C2)CC1

Molecular Formula

C26H28D3Cl2N7O3

Molecular Weight

563.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Guagnano V, et al. Discovery of 3- (2,6-Dichloro-3,5-dimethoxy-phenyl) -1-{6-[4- (4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T